Steven D. Gore, MD

Professor of Internal Medicine (Hematology); Director of Hematologic Malignancies

Physician Biography

Dr. Gore came to Yale in November 2013 following 23 years on the faculty at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. Dr. Gore is an international authority on myelodysplastic syndromes (MDS) and other forms of leukemia. He is particularly known for his novel clinical and translational trials in MDS and leukemia, using drugs which target epigenetic abnormalities in leukemia cells. He is a leader in the leukemia effort of the Eastern Cooperative Oncology Group and is a member of the MDS committee of the National Cancer Care Network.

Clinical Interests

  • Hematology
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations


Cancer Center: Hematology Program

Yale Medical Group

Board Certifications

  • Internal Medicine AB of Internal Medicine (1987)

  • Medical Oncology AB of Internal Medicine (1989)

Clinical Trials

Conditions Study Title
Myeloid and Monocytic Leukemia Azacitidine subcutaneous in combo w/ MEDI4736 in higher-risk MDS or elderly AML subjects
Leukemia, other ADCT-402 in Patients w/ Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Leukemia, other SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First CR
Leukemia, other Phase I-II Nintendanib+placebo in combo with induction chemo in first relapse acute myeloid leukemia
Leukemia, other ACE-536 to Treat Anemia Due to Very Low,Low or Intermediate Risk Myelodysplastic Syndrome (MEDALIST)
Lymphoid Leukemia, Phase I A Safety and Pharmacokinetic Study of BTCT4465A in NHL and CLL
Myeloid and Monocytic Leukemia Imetelstat Transfusion-Dependent Subjects w/ IPSS Low or Intermediate-1 Risk MDS that is RR to ESA
Myeloid and Monocytic Leukemia, Phase I CC-90002 in subjects w/ actue myeloid leukemia and high-risk myelodysplastic syndrome
Myeloid and Monocytic Leukemia, Phase I Pomalidomide After combo Chemotherapy in Treating Patients w/ Newly Diagnosed AML and High-Risk MDS
Leukemia, other ASP2215 vs Salvage Chemotherapy in Relapsed or Refractory AML with FLT3 Mutation
Leukemia, other, Myeloid and Monocytic Leukemia Nivolumab in Eliminating Disease,Preventing Relapse in Patients w/Acute AML in remission after Chemo
Leukemia, other, Phase I Ph I: ASP2215 in Combination With Induction and Consolidation Chemo in Pts With Newly Diagnosed AML
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic, Phase I An Open-Label Study of a Novel JAK-inhibitor,INCB052793,Given to Patients With Advanced Malignancies
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia, Phase I Phase 1 of IPI in Relapsed/Refractory High Risk MDS and AML
Myeloid and Monocytic Leukemia Ph 3: Randomized Study of Quizartinib v Salvage Chemo for FLT3-ITD Positive AML
Myeloid and Monocytic Leukemia Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)
Lymphoid Leukemia, Pediatrics T cell Leukemia; T cell Lymphoma
Leukemia, other E1910: Blinatumomab for Frontline BCR-ABL (-) B Cell ALL

Edit this profile

Contact Info

Steven D. Gore, MD
Patient Care Location
Yale Cancer Center-YNHHYale-New Haven Hospital
20 York Street, Ste 7th Floor

New Haven, CT 06510
View on map...
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028

Curriculum Vitae